Skip to main content
Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

First-Ever 85% CRP Reduction with Quarterly Dosing: Tourmaline's Breakthrough in Heart Disease Trial

Summary by stocktitan.net
Biotech's pacibekitug achieves significant reductions in multiple cardiovascular biomarkers across all dosing arms. First IL-6 inhibitor showing deep CRP reductions with quarterly dosing.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

stocktitan.netstocktitan.net

First-Ever 85% CRP Reduction with Quarterly Dosing: Tourmaline's Breakthrough in Heart Disease Trial

Biotech's pacibekitug achieves significant reductions in multiple cardiovascular biomarkers across all dosing arms. First IL-6 inhibitor showing deep CRP reductions with quarterly dosing.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

stocktitan.net broke the news in on Sunday, August 31, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Biotech icon

Biotech

News
For You
SearchBlindspotLocal